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OBJECTIVE: The aim of the present study was to assess nasal mucociliary clearance, mucus properties and
inflammation in smokers and subjects enrolled in a Smoking Cessation Program (referred to as quitters).
METHOD: A total of 33 subjects with a median (IQR) smoking history of 34 (20-58) pack years were examined for
nasal mucociliary clearance using a saccharine transit test, mucus properties using contact angle and sneeze
clearability tests, and quantification of inflammatory and epithelial cells, IL-6 and IL-8 concentrations in nasal
lavage fluid. Twenty quitters (mean age: 51 years, 9 male) were assessed at baseline, 1 month, 3 months and
12 months after smoking cessation, and 13 smokers (mean age: 52 years, 6 male) were assessed at baseline and
after 12 months. Clinicaltrials.gov: NCT02136550.
RESULTS: Smokers and quitters showed similar demographic characteristics and morbidities. At baseline, all
subjects showed impaired nasal mucociliary clearance (mean 17.6 min), although 63% and 85% of the quitters
demonstrated significant nasal mucociliary clearance improvement at 1 month and 12 months, respectively. At
12 months, quitters also showed mucus sneeze clearability improvement (B26%), an increased number of
macrophages (2-fold) and no changes in mucus contact angle or cytokine concentrations.
CONCLUSION: This study showed that smoking cessation induced early improvements in nasal mucociliary
clearance independent of mucus properties and inflammation. Changes in mucus properties were observed
after only 12 months of smoking cessation.
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’ INTRODUCTION
Tobacco smoking is the most relevant, evitable global risk
factor for death. Long-term cigarette smoking is associated
with numerous structural and functional alterations in the
respiratory system. In the nose and upper airways, long-term
cigarette smoking affects cilia structure and function (1-3),
which can lead to altered mucociliary clearance (MCC) (4-8).
MCC is a primary defense mechanism that protects the
human airways and lungs against the harmful effects of
inhaled particles. Thus, defects in these defense mechanisms
contribute to inflammation and obstruction of the small
airways (9) and increased susceptibility to respiratory
infections (10,11), lung injury, tissue repair problems, chronic
dysfunction and progression of respiratory diseases (12,13).
Smoking cessation is an important part of a comprehen-
sive approach to tobacco control (14) and is the best strategy
to avoid respiratory risks and complications, to improve
chronic obstructive pulmonary disease (COPD) (15) and to
reduce cardiovascular risk and mortality (16-18). A few
studies have focused on nasal MCC and inflammation and
reported improvements after smoking cessation, althoughDOI: 10.6061/clinics/2016(06)10
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mucus properties have not been investigated. The aim of this
study was to assess nasal MCC, mucus properties and
inflammation at 1, 3 and 12 months after smoking cessation.
’ MATERIAL AND METHODS
Study population
This study protocol was approved by the Ethical Commit-
tee of São Paulo University, São Paulo, Brazil (CEP-FMUSP
235/14) and was conducted in accordance with the Helsinki
Declaration (1983). This study is registered at Clinicaltrials.
gov (NCT02136550). We recruited subjects (aged above
30 years) from the Ambulatório de Pneumologia, Hospital
das Clínicas da Faculdade de Medicina da Universidade de
São Paulo, admitted to the Smoking Cessation Program
(referred to as quitters). We also recruited smokers from the
Faculdade de Medicina da Universidade de São Paulo. The
exclusion criteria included the inability to taste saccharine,
previous nasal surgery or trauma and infection in the upper
and/or lower airways in the 30 days before clinical
examination. All participants provided written informed
consent.
Study design
The subjects were assessed at the University Laboratory of
Pulmonary Defense from 1 P.M. until 6 P.M. Smokers and
quitters were assessed at baseline and after 12 months.
Quitters were also assessed after 1 and 3 months (Figure 1).
For all assessments, subjects were asked to avoid coffee, tea,
alcohol and green vegetables at least 12 h prior to analysis.
We also asked smokers to refrain from smoking cigarettes at
least 2 h prior to measurements. Subjects underwent a
physical examination with measurements of arterial blood
pressure (mmHg), heart rate (bpm) and pulse oximetry (%)
after 10 min of resting.
A current smoker was defined as a subject who had
smoked X100 cigarettes and who currently smoked at
least one cigarette per day according to the guidelines of
the World Health Organization. Subjects enrolled in our
Smoking Cessation Program had received a combination of
counselling and medication (nicotine replacement therapy,
administration of bupropion and/or nortriptyline) for a
3-month period. All subjects enrolled into this study were
investigated for concentrations of exhaled carbon monoxide
(CO) and cotinine levels in the nasal lavage fluid (NLF). CO
was measured using a Micro CO analyzer (Cardinal Health
U.K.232 Ltd., Chatham, UK). Subjects were asked to exhale
slowly from their total lung capacity with a constant
expiratory flow of 5-6 L.min-1 over 10 to 15 sec. Smoking
cessation was defined as an exhaled CO o10 ppm and
cotinine levels in NLF o10 ng/mL (7).
We also collected demographic data and a clinical history
and performed nasal MCC, nasal mucus collection for sneeze
clearability and contact angle analysis and NLF collection to
measure inflammatory and epithelial cells and cytokine
production.
Nasal mucociliary clearance
The subjects were evaluated in standardized conditions
of a quiet room with a 21-23oC ambient temperature and
63-71% relative humidity. The subjects remained in a seated
position. Briefly, nasal MCC was assessed with the sacchar-
ine transit test (STT) (7,19). The STT measures the elapsed
time between saccharine deposition 2 cm inside the
non-obstructed nostril and the first perception of a sweet
taste. We asked subjects to maintain normal ventilation and
to avoid deep breaths, coughing, sneezing, sniffing or talking
during the test. A normal value for a healthy adult is below
12 min (19).
Mucus collection and analysis
After the STT, we collected nasal mucus with the aid of a
soft brush and stored the sample in the freezer (-80oC) for
further analysis of mucus sneeze clearability and the mucus
contact angle. To evaluate mucus sneeze clearability in vitro,
we used a machine that simulates a cough or sneeze,
Figure 1 - Longitudinal study design.
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as adapted by King et al. (20). A model acrylic ‘‘trachea’’
cylinder with a cross section of 4 mm and a length of
133 mm was connected to a tank containing pressurized air
with a flow of approximately 6 L/s (21). A sample of mucus
(25 ml) was deposited in a thin line across the base of the
acrylic trachea. Sneeze clearability was measured in milli-
meters after a single maneuver as the transport distance
from the point where the sample was positioned. Wett-
ability refers to the ability to spread over a solid planar
surface and is characterized by the contact angle, which is
formed between the air-fluid interface and the planar glass.
To analyze the contact angle, we used a planar glass pre-
treated with a sulphochromic solution and washed with
deionized water several times. Five minutes after mucus
sample (25 ml) deposition on the planar glass, the measure-
ment of the contact angle was registered using a stereo-
microscope (Stemi 2000C, Carl Zeiss, Göttinger, Germany)
connected to a camera (Axiocam HSC, Carl Zeiss, Göttinger,
Germany) and to a microcomputer with an image pro-
gram (Interactive AxionVison 4.7, Carl Zeiss, Göttinger,
Germany) (7,19).
Nasal lavage collection
This method has been described previously (7,22). Briefly,
subjects were asked to tilt their head back at 30o and to close
the nasopharynx with the soft palate. Five milliliters of room
temperature isotonic sodium chloride solution (0.9% NaCl)
was instilled into each nostril. After 10 sec, the subjects blew
their nose forcefully into a sterile plastic container. The
average recovery of fluid from the NLF was approximately
70-75%. The NLF was centrifuged (10 min, 300 g, 5oC) and
the supernatant was separated from the pellet and divided
into five aliquots of 500 ml. The aliquots were coded (for
blinding purposes) and stored at –80oC for up to 4 weeks to
determine the cytokine levels. The cell pellet was used for
total and differential cells counts as previously described
(7,22).
Total and differential cells counts in the NLF
The cell pellet was resuspended in one milliliter of
phosphate-buffered saline solution (7,22). Thereafter, 20 ml
of the mixed solution was added to a Neubauer chamber,
and the cells were counted using a 400x light microscope
(Olympus CH2, Olympus America Inc., Palo Alto, USA). For
differential cell counts, 100 ml of the mixed solution was
centrifuged using a cytospin (96 g, 25oC, 6 min) to obtain two
slides for differential cell counts. The slides were stained
according to the May–Grunwald–Giemsa method and
100 cells were counted with damaged cells excluded (7,22).
The percentages of epithelial cells, neutrophils, eosinophils,
lymphocytes and macrophages were calculated as fractions
of the total cells. Differential cell counts were performed with
the aid of a 1,000x light microscope (Olympus CH2,
Olympus America Inc., Palo Alto, USA) by two different
observers.
Measurement of cotinine and cytokines in the NLF
To determine the cotinine levels in the NLF, a high-
sensitivity salivary cotinine quantitative enzyme immunoassay
(DRG International, Inc., USA) was used according to
manufacturer ’s instructions. The lower detection limit
was 0.1 and the standard curve was fitted between 0 and
50 ng/ml [7)].
The concentrations of interleukin IL-6 and IL-8 in the NLF
were determined using high-sensitivity enzyme immunoas-
says (Quantikine HS, R&D Systems Inc., Minneapolis, USA).
The assays were performed as described by the manufac-
turer. The reported detection limits were 0.039 pg/ml for IL-6
and 0.11 pg/ml for IL-8, with the standard curve fitted
between 0 and 10 pg/ml for IL-6 and 0 and 2,000 pg/ml for
IL-8.
Statistical analysis
Data were expressed as the mean ± standard deviation
(SD) or median (IQR) when specified. Categorical variables
were analyzed by means of the Chi-square test. Analysis of
variance (ANOVA) for repeated measures was used to
analyze data across the study period with Bonferroni post-
hoc tests. Differences were considered statistically significant
at a p-value o0.05.
’ RESULTS
Twenty subjects in each group entered the study. Seven
smokers revoked their informed consent and were excluded
from the analysis. Twenty quitters and thirteen smokers
were followed over 12 months. At baseline, the smokers
and quitters showed similar demographic characteristics,
frequencies of morbidities and use of medications (hyper-
tensive, beta-blocker and hydroclorotiazide) (Table 1).
Furthermore, all current smokers had similar smoking
histories of B 42 pack-years. No significant differences were
found between smokers and quitters at baseline in systolic
blood pressure values (116.1±12.7 and 122.5±11.5 mmHg,
respectively), heart rate (82±9 and 81±13 bpm, respec-
tively), and peripheric oxygenation (95±3 and 95±2%,
respectively). However, diastolic blood pressure was higher
in subjects in the quitter group (B 79 mmHg) compared to
the smoking group (B 73 mmHg, p=0.039). These clinical
variables did not vary during the study period in either
group.
At baseline, assessments of exhaled CO and cotinine levels
in NLF showed similar concentrations in smokers and
quitters (Figure 2) One month after quitting with the
Table 1 - Demographic and clinical characteristics of smokers
and quitters at baseline of the study are presented as mean ± SD
and analyzed by means of T-test (*) or number (proportion) for
categorical variables that were analyzed by means of Chi-Square
test.
Smokers Quitters p-value
n=13 n=20
Age, mean ± SD, years 52±10 51±9 0.860*
Male, n (%) 6 (46) 9 (45) 0.948
BMI, mean ± SD, kg/m2 25.5±4.6 27.8±6.1 0.259*
Pack-years, mean ± SD 45±28 40±27 0.450*
Morbidities, n (%)
Hypertension 2 (15) 9 (45) 0.078
Diabetes 0 (0) 1 (5) 0.413
Depression 3 (23) 6 (30) 0.663
Myocardial infarction 1 (8) 1 (5) 0.751
Arrhythmia 1 (8) 0 (0) 0.208
Medications, n (%)
Anti-hypertensive 0 (0) 3 (15) 0.143
Beta-blocker 1 (8) 0 (0) 0.208
Diuretics 1 (8) 2 (10) 0.822
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Smoking Cessation Program, quitters showed a significant
decrease in concentrations of exhaled CO that remained low
compared with smokers over the observation period of
12 months (Figure 2). Cotinine concentrations in the NLF of
quitters decreased after 3 months and remained low after
12 months of smoking cessation.
At baseline, the STT values were prolonged in both
groups (Figure 3). After 12 months, smokers showed a
similar pattern of impaired nasal MCC. In contrast, quitters
showed significant decreases in STT values from 1 month to
12 months. Mucus clearability by sneeze was similar
between groups at baseline. The nasal mucus contact angle
was similar between the two groups at baseline and did not
change during the study period in smokers (33±7o and
35±10o, p=0.550) or quitters (36±8o and 32±8o, p=0.225).
However, quitters demonstrated improvements in mucus
transportability properties after 12 months (Figure 3).
At baseline, the total numbers of inflammatory and epithelial
cells in the NLF were similar between the two groups. However,
smokers showed a higher number of macrophages compared
with quitters (Table 2). After 12 months, the quitters showed an
increase in the number of macrophages in the NLF (po0.001)
with no significant differences between groups. The concentra-
tions of IL-6 and IL-8 were similar between groups at baseline
and after 12 months.
’ DISCUSSION
We conducted this 12-month longitudinal study in long-
term smokers to investigate the effects of smoking cessation
Figure 2 - Concentrations of cotinine (ng/mL) and exhaled carbon monoxide (ppm) in smokers and quitters throughout the study.
Figure 3 - Nasal mucociliary clearance according to the saccharine transit time (min) and mucus clearability by sneeze (mm) in smokers
and quitters throughout the study.
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on nasal MCC, mucus properties and inflammation. Smok-
ing cessation improved nasal MCC after 1 month of recovery,
but this improvement was not accompanied by changes in
nasal mucus properties or inflammation. Smoking cessation
also induced late changes in mucus properties; after
12 months, quitters showed faster mucus clearability by
high-flow compared with current smokers.
Tobacco smoking has been associated with increased
oxidative stress, airway and lung inflammation (23),
impaired anion transport (24) and abnormalities in cilia
ultrastructure (1,2,25) and cilia genesis (26). Studies that
assessed young smokers (7), adults aged418 years (27,28) or
light smokers (o15 cigarettes/day) (29,30) have shown
faster or similar STT results compared with nonsmokers
(Table 3 for review). This response may be associated with
the preservation of protective mechanisms of airway and
lung transport. In young smokers, tobacco smoke induces an
early response of ciliary beat frequency acceleration in the
nasal ciliated epithelium (31), which in turn results in faster
nasal MCC, as previously reported (7). However, the effects
of long-term tobacco smoking on MCC remain under debate.
Several studies have reported significant STT prolongation in
long-term smokers (3-5,32-34) and smokers with COPD (35).
These impairments may be associated with reductions in
ciliary beat frequency (36) or in the number of cilia in the
presence of a normal ciliary beat frequency (6). In the current
work, 76% of smokers showed prolonged STT at baseline.
However, quitting smoking improved nasal MCC by
63% after 1 month and after 3 and 12 months, 85% of
subjects reached a normal STT (p 12 minutes) with similar
values as healthy nonsmokers of the same age (19).
We also focused on changes in mucus properties and
inflammation after smoking cessation. Mucus physical
properties, ciliary beating frequency and the cilia-mucus
interaction are deterministic elements of MCC. We found no
changes in mucus surface contact angle during the study in
either group, which was consistent with a previous study (7).
However, 12 months after quitting smoking, quitters showed
increased mucus sneeze transportability. This result is
consistent with previous studies showing that mucus
viscoelastic properties may be less clearable by cough in
smokers compared with nonsmokers (37). We did not find
significant changes over 12 months in the number of ciliated
cells in the NLF of the two groups of subjects. Some smoking
cessation-related mechanistic pathways could explain the
early improvement in MCC, such as normalization of cilia
structure and genesis (25,26) and ciliary beating function.
Mucus clearability by high-flow could be associated with
restoration of the ionic transport function and mucus
hydration at the basolateral membrane (24). However, ciliary
beating frequency, cilia structure and epithelium analysis
were beyond the scope of this study.
The present study also found that smokers at baseline
showed evidence of nasal inflammation, specifically an
increased number of inflammatory cells and cytokine levels
in NLF. However, in our previous study with young healthy
smokers (7), quitters showed a similar number of macro-
phages (B15 cells) compared to nonsmokers (B14 cells).
Thus, we cannot exclude the possibility that quitters in the
present study were already reducing their smoking load at
the beginning of the study (baseline) or that they could take
longer to definitely quit smoking. Additionally, after smok-
ing cessation, there were only small changes in the number of
macrophages combined with no changes in pro-inflamma-
tory cytokines (IL-6 and IL-8) in the NLF. However, our
results are corroborated by those of others showing main-
tenance of inflammation in bronchial biopsies of COPD
patients (38,39), which can be explained by mechanisms such
as airway chronic colonization by viral or bacterial
pathogens.
This study has some limitations. First, the sample size of
smokers was small and not paired with the quitter group.
Indeed, we began with 20 subjects in each group as
determined by the sample size calculation. However, seven
smokers removed their informed consent after baseline and
were excluded from the study. Another limitation was that we
may have overestimated the number of subjects who
effectively progressed in the smoking cessation program
because some subjects may have remained in the quitters
group but in fact reinitiated their smoking habit. However, we
found it useful to quantify CO in exhaled air and cotinine in
the NLF to assess smoking status in the last 2 and
12 hours, respectively, at several time-points of the study
and quitters showed a significant decrease in exhaled CO after
1 month of recovery. To highlight differences between the two
methods, quitters showed a significant decrease in NLF
cotinine levels only after 3 months of recovery. We raise the
possibility that this result may be associated with the nicotine
replacement therapy delivered during the smoking cessation
program. However, we cannot exclude the possibility that
subjects may not have adhered to the cessation program after
1 month, taking longer to definitively quit smoking. We did
not measure ciliary beat frequency or analyze cilia structure
because these methods, such as nasal brushings or biopsies,
Table 2 - Total number of inflammatory and epithelial cells and cytokine concentrations (pg/mL) in the nasal lavage fluid of smokers
and quitters throughout the study. Data are presented as mean values (SD).
Smokers n=13 Quitters n=20
Baseline 12 months Baseline 1 month 3 months 12 months
Total cells x 10-6 74 (85) 97 (60) 86 (200) 36 (26) 85 (87) 58 (37)
Neutrophils 24 (21) 44 (37) 27 (28) 27 (25) 33 (29) 24 (18)
Lymphocytes 9 (7) 7 (7) 10 (10) 11 (9) 9 (6) 7 (5)
Macrophages 33 (14) 27 (20) 15 (11) f 19 (14) 17 (11) 44 (15)*
Ciliated cells 34 (15) 21 (17) 21 (25) 37 (23) 22 (22) 21 (5)
Goblet cells 2 (3) 1 (3) 10 (14) 6 (9) 10 (8) 3 (3)
Cytokines
Interleukin-6 2.7 (3.7) 3.9 (4.3) 2.3 (3.2) 3.1 (3.1) 2.0 (2.5) 2.3 (2.0)
Interleukin-8 584.4 (628.9) 770.4 (518.7) 415.7 (589.3) 308.2 (385.4) 352.9 (275.6) 472.4 (398.5)
* po0.001 vs. baseline
f p=0.006 vs. other group at the same period of time
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are difficult and more invasive or traumatic to perform in
humans. Another limitation was that counting cells with a
two-dimensional method does not take into account the
volume of the cell. However, we were able to obtain an
inflammatory pattern and epithelial cell profile in both
groups. Additionally, we are aware that there are studies
showing a reduction in MCC with the use of beta-blockers
(40) and furosemide (41) via the blockade of water and ionic
transport. However, no subject in the present study used
furosemide, and only one smoker (8%) used a beta-blocker,
which remained the same throughout the study period.
In conclusion, this study showed early improvement in nasal
MCC after smoking cessation. Improvements in mucus proper-
ties were observed after 12 months of smoking cessation.
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Table 3 - A review of mean (±SD) or median (IQR) values for the saccharine transit time in nonsmokers, passive smokers, current
smokers and ex-smokers.
Authors N Subjects Age (years) Smoking habit (pack-year) STT (min)
Stanley et al. 1986 (3) Total n=27 33 Nonsmokers 11.1±3.8
Smokers 20.8±9.3*
Alfaro-Monge & Soda-Merhy 1995 (33) Total n=100 Nonsmokers 10.3
Smokers 13.6*
Nakagawa et al. 2005 (5) Total n=16 32±14 Nonsmokers 10.5
Smokers 22.0*
Karaman & Tek 2009 (4) Nonsmokers n=20 18-57 Nonsmokers 12.1±1.9
Smokers n=20 Smokers 4 1 26.4±1.8*
Piotrowska et al. 2010 (32) Nonsmokers n=21 59 ± 9 Nonsmokers 9.9±0.5
COPD n=42 50-84 COPD Smokers: 35.8±13.7 16.3±1.6*
COPD Ex-smokers 11.2±0.5
Ramos et al. 2011 (34) Nonsmokers n=33 52±14 Nonsmokers 8 (7-13)
Smokers n=33 49±12 Smokers: 44±25 13 (8-25)*
Ito et al. 2015 (35) Nonsmokers n=26 60±11 Nonsmokers 8 (6-16)
Smokers n=27 62±8 Smokers: 38.8±27.6 15.9 (10-27)*
COPD Ex-smokers n=23 58±8 COPD Ex-smokers: 31.5±24.8 9.7 (6-12)
COPD Smokers n=17 61±6 COPD Smokers: 39.9±21.4 16.5 (11-28)*
Littlejohn et al. 1992 (27) Total n=10 4 18 Smokers 11.7±3.3
Mahakit & Pumhirun, 1995 (28) Total n=40 Nonsmokers 12.0
Smokers 12.4±3.0
Proenc¸a et al. 2012 (30) Nonsmokers n=30 49 (44-5) Nonsmokers 8 (8-11)
Smokers n=52 50 (43-50) Smokers: 62 (36-78) 10 (10-13)
Light n=17 51 (41-54) Light: 23 (23-36) 9 (7-11)
Moderate n=22 47 (38-49) Moderate: 15 (13-23) 13 (11-17)
Heavy n=13 50 (41-57) Heavy: 25 (19-30) 13 (10-21)
Habesoglu et al. 2012 (29) Nonsmokers n=15 28±11 Nonsmokers 6.4±1.6
Passive smokers n=15 29±12 Passive smokers: 12.6±4.7*
o 10 cigarettes/day 9.3±4.7
410 cigarettes/day 15.5±2.0
Active smokers n=17 28±11 Active smokers 23.6±12.4*
o 10 cigarettes/day 11.0±3.5
10-20 cigarettes/day 24.3±3.0
420 cigarettes/day 35.0±14.9
Nicola et al. 2014 (7) Nonsmokers n=32 21±4 7.7±4.1
Smokers n=40 19±1 Healthy smokers: o 2,5 5.7±3.4*
24±5 Healthy smokers: 4 2,5 5.9±2.9*
Pagliuca et al. 2015 (8) Nonsmokers n=30 53±6 11.7
Ex-smokers n=30 51±7 Ex-smokers: 25±8
cigarettes/day
11.8
Smokers n=3 52±6 Smokers: 25±6 cigarettes/day 15.6
Utiyama et al. 2016 Ex-smokers n-=20 51±9 Ex- smokers: 40±27 8.2±3.1
Smokers n=13 52±10 Smokers: 45±28 17.9±10.1*
* po0.05 vs. nonsmokers
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